Company profile
SOL-GEL TECHNOLOGIES LTD.
NASDAQ:SLGLBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| PATIDEGIB | phase3 | — | 4 | completed, terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (15)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03564145 | phase3 | terminated | 2018-09-12 | 2019-11-13 | Sol-Gel Technologies, Ltd. | A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea |
| NCT00940992 | phase2 | completed | 2012-01-01 | 2012-09-01 | Sol-Gel Technologies, Ltd. | A Study of DER 45-EV Gel to Treat Rosacea |
| NCT04155190 | phase2 | terminated | 2019-12-20 | 2021-04-23 | Sol-Gel Technologies, Ltd. | A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC |
| NCT03564119 | phase3 | completed | 2018-06-21 | 2019-06-10 | Sol-Gel Technologies, Ltd. | A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea |
| NCT03448939 | phase3 | completed | 2018-06-18 | 2019-05-24 | Sol-Gel Technologies, Ltd. | A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea |
FDA applications (0)
No records yet.